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INTRODUCTION
When compared with white males, black 
males have higher incidence and worse 
outcomes of prostate cancer. In the US 
where routine screening with prostate 
specific antigen (PSA) is widespread, 
African–Americans are around 1.6 times 
more likely to be diagnosed with prostate 
cancer and are more than twice as likely 
to die from the disease than their white 
counterparts.1 In the UK, where PSA 
screening is not recommended, prostate 
cancer incidence is approximately three 
times higher,2 and case-specific mortality 
rates are 35% greater in black males 
compared with white males.3 These ethnic 
differences in mortality, in addition to 
possible biological differences, may arise 
at several points in the diagnostic and 
treatment pathways.4 
The present study focuses on diagnosis. 
Some of the differences in black versus 
white mortality rates may be linked to 
diagnostic delay, although existing,  albeit 
weak, UK studies found no evidence of such 
a relationship.5 Black males also have worse 
staging at diagnosis6 and are 1.7 times more 
likely to present as an emergency.4
Prostate cancer diagnosis is generally 
preceded by symptoms (although the 
possibility of cancer may not be recognised), 
followed by presentation to primary care, 
where initial assessment may lead to 
investigation or referral.7,8 The first interval 
is pre-presentational; patients may delay 
presenting to primary care due to fear of 
cancer. Non-recognition or misattribution 
of cancer symptoms, comorbidity, 
socioeconomic deprivation, and self-
medication may also affect this process. 
In minority ethnic groups, stigma, cultural 
and religious preferences, language and 
communication barriers, as well as racial 
discrimination, are additional possible 
contributory factors to delay.9
Once patients present to primary care, 
however, the decision regarding whether or 
not to investigate for cancer is determined, 
in the main, by GPs. National guidance 
recommends shared decision making 
between doctor and patient,10 but it is 
unknown to what extent this is achieved in 
reality. Lower urinary tract symptoms, such 
as urgency and hesitancy, are common, 
and none is particularly suggestive of 
malignant, as opposed to benign, disease.11 
Both digital rectal examination and PSA 
testing have false positives and false 
negatives. Furthermore, prostate cancer 
treatments may lead to complications, 
such as incontinence or impotence; men 
knowing this may decline testing. 
Patient views on testing for cancer have 
rarely been investigated. In a vignette 
(hypothetical scenario)-based study in 2014, 
Banks et al reported that patients in the 
UK preferred to be investigated for lung, 
pancreatic, and colorectal cancer, even 
at low risk levels.12 That study was not 
powered to identify any ethnic differences 
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Abstract
Background
Minority ethnic groups in the UK have worse 
outcomes for some cancer types compared 
with the white majority. Black males have worse 
staging at diagnosis of prostate cancer and often 
present as emergencies, suggesting possible 
delays in the diagnostic pathway. Delay may arise 
from lower awareness of cancer symptoms, 
reluctance to report symptoms, reduced desire 
for investigation, or a combination of these. 
Reduced desire for investigation was examined 
in this study 
Aim
To investigate whether black males in the UK 
would choose to be tested for prostate cancer 
compared with the white majority.
Design and setting
A vignette (hypothetical scenario)-based, 
electronic survey of male patients aged 
≥40 years from four general practices in Bristol, 
UK.
Method
The vignettes described possible prostate cancer 
symptoms (equating to risk levels of 2%, 5%, 
and 10%), investigative procedures, and possible 
outcomes. Participants indicated whether they 
would choose investigation in these scenarios. 
Analysis used logistic regression, with preference 
for investigation as the outcome variable and 
ethnicity as the main explanatory variable.
Results
In total, 449 (81%) of 555 participants opted for 
investigation, regardless of risk levels; of these, 
the acceptance rate was 94% (251 out of 267) 
among white males and 70% (198 out of 285) 
among black males. In multivariable analyses, 
preference for investigation was lower in black 
males, even after controlling for relevant 
confounding factors including specific risk level 
(odds ratio 0.13; 95% confidence interval = 0.07 
to 0.25; P<0.001).  
Conclusion
Black males are less likely to opt for investigation 
at any risk level of prostate cancer compared with 
white males. This may explain some of their late-
stage presentation at diagnosis and subsequent 
poorer outcomes.
Keywords
ethnic groups; primary health care; prostate 
cancer. 
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in the preference for cancer investigation. 
To address this, the current study adopted a 
similar approach to investigate whether the 
preference for prostate cancer investigation 
in black patients is comparable with that of 
white patients. 
METHOD
Design and participants 
This was a vignette-based survey of primary 
care patients, performed between January 
2014 and April 2014. Participants were 
males aged ≥40 years, attending four 
general practices in Bristol, UK. Selected 
practices (selected from 10 potentially 
eligible general practices) were those 
located in areas with a high concentration 
of minority ethnic groups; these were 
recruited through the local Primary Care 
Research Network. 
The survey was administered via a 
tablet computer (iPad) and gathered 




• ethnicity (defined using the 2001 UK 
Census groupings);
• income;
• level of education;
• employment status;
• previous history of cancer (personal, 
family, or close friends);
• travel time to hospital; and 
• convenience of the nearest main hospital. 
Three different vignettes each included a 
description of prostate cancer symptoms, or 
symptom combinations, and the estimated 
risk of prostate cancer (2%, 5%, and 10%); 
symptoms were portrayed numerically 
and pictorially. The selection of symptom 
profiles was based on clinical experience, 
primary care evidence, and guidelines from 
the National Institute for Health and Care 
Excellence (NICE).10,11 Table 1 outlines each 
vignette; Appendix 1 shows the screens 
and exact wording seen by the participants 
The vignettes also gave information about 
physical examination, relevant tests, and 
differential diagnoses with an approximate 
prognosis should prostate cancer be 
detected. 
Finally, the vignettes summarised all the 
information and requested participants to 
indicate whether or not they would choose 
diagnostic investigation if they had the 
symptoms in question. Participants were 
subsequently asked to choose from a 
predefined list of reasons for choosing or 
declining investigation. Extensive piloting 
of vignettes and the technology had been 
performed for a previous study, including 
two cycles with patient representatives;12 
the piloting in this extension involved 
informal testing of terminology relating 
to urinary symptoms and risk with black 
community groups. 
Procedure 
Participants awaiting their primary 
care appointment were approached 
opportunistically by one researcher, who 
had the study information on the iPad screen 
and on paper. Patients who appeared to be 
<40 years of age were avoided because 
prostate cancer is rare in younger males. 
Before completing the survey, selected 
participants gave or declined oral informed 
consent, supplemented by a consent screen 
on the iPad. Occasionally, the practice’s 
bilingual link worker or professional 
interpreters helped clarify/translate the 
vignette. Participants could complete up 
to two vignettes, selected at random and 
at different risk levels. In addition, they 
were able to exit the survey at any stage 
if they desired or were called into their 
consultation.
Statistical analysis 
The aim was to survey at least 572 males 
(286 of each ethnicity), providing 90% power 
at the 5% significance level to detect a 
difference between the groups in preference 
for investigation, 80% versus 90%, with 
the latter figure being the outcome in the 
earlier study.12
Black males in this study were those 
who self-identified as black–black British 
African or black–black British Caribbean, 
while white males were self-identified white 
British. Males who identified with ethnic 
groups other than the above categories 
were classified as ‘other groups’ and were 
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How this fits in
Black males have worse outcomes in 
several cancer types, including prostate 
cancer, and they present more frequently 
to primary care before diagnosis when 
compared with white males. It is not certain 
whether black males have different 
attitudes to testing for cancer, which could 
explain this. This vignette-based study 
showed a considerably lower preference 
for testing in black males. Furthermore, 
their preference for testing was lower at the 
lowest risk level.
Table 1. Prostate cancer 
symptoms and associated risk 
levels, as described in the 
vignette
Prostate cancer symptom(s)a Risk level, %
Hesitancy (difficulties starting 2 
  to urinate)
Frequency/urgency (needing to 5 
  rush to the toilet to urinate) 
Hesitancy
Weight loss 10 
Frequency/urgency  
Hesitancy
aAll symptoms last 6 weeks.
omitted from the analyses due to small 
numbers. 
Participant characteristics were 
summarised using simple descriptive 
statistics. Few participants completed a 
second vignette, so analyses of preferences 
for investigation were restricted to the 
first. Logistic regression was used to 
compare the binary outcome preference 
for investigation (opting for investigation 
versus not doing so) between white and 
black groups, firstly without adjustment 
and, secondly, adjusted for potential 
confounders, including age, employment 
status, convenience of hospital, previous 
history of cancer, and prostate cancer risk. 
As a second test of the possible effect 
of age on the main outcome, a stratified 
analysis was performed using three age 
groups. However, as expected from the 
main analysis, this was insignificant; as 
such, the results have been omitted. All 




Ten potentially eligible general practices 
expressed interest in participation, of these, 
four were selected, one had data on patients’ 
ethnicity, with 2.5% of the practice patients 
reported as being black.13 This practice 
was selected despite having a relatively 
low percentage of black males, to increase 
generalisability. The remaining three were 
located in areas with a high concentration 
of black African or black Caribbean people 
(40%, 40%, and 17%, respectively) when 
compared with an overall figure of 3.3% for 
England and Wales.14 
The mean number of patients registered 
in the practices was 12 567 (range 5176–
18 035); the average practice size in 
England is 7041.13 All four practices were 
in areas of considerable socioeconomic 
deprivation, when compared with the 
average Index of Multiple Deprivation (IMD) 
score for England in 2012. The mean IMD 
score for the four practices was 36.9 (range 
29.6–43.5), compared with an average of 
21.8 for England in 2012.13 
Patients’ characteristics
In total, 756 males were asked to 
participate; 147 either declined (n = 128) 
or were <40 years of age (n = 19). Four 
omitted the questions on ethnicity, and 
50 self-identified with other ethnic groups 
therefore were excluded; this left 555 
participants for analysis. Figure 1 shows 
the participant selection process and the 
number of vignettes completed. Table 2 
shows participants’ characteristics by 
ethnic group. 
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Table 2. Participants’ (n = 555)a characteristics by black (n = 286) and 
white (n = 269) males
Characteristics Black males, % White males, %
Age, years  
 40–59 74 39 
 60–69 11 28 
 ≥70 15 33
Income, £  
 <10 000 41 44 
 10 000–25 000 54 52 
 25 000–40 000 5 5
Highest educational qualification 
 None  29 30 
 GCSE/equivalent 36 33 
 Vocational or A-level 17 27 
 Degree or more advanced  18 10
Employment status 
 Retired  21 51 
 Not in paid employment  22 14 
 Working part time 15 16 
 Working full time 42 19
Convenience of hospital  
 Very convenient  69 82 
 Quite convenient  26 16 
 Quite inconvenient  4 2 
 Very inconvenient  2 0
Travel time to hospital, hours  
 <0.5  93 95 
 0.5–1 7 5
Previously diagnosed with cancer 3 4
Family or close friend previously  39 59 
diagnosed with cancer
 aThe lowest sample size was 552 of a maximum of 555. GCSE = General Certificate of Secondary Education.
Participants offered vignette
Total n = 756
Excluded n = 4





Excluded n = 147
Declined participation, 
n = 128
Aged <40 years n = 19
White other n = 16
Asian other n = 8
Bangladeshi n = 7
Black other n = 4
Pakistani n = 4
White Irish n = 3
Indian n = 2
Mixed African n = 2
Mixed Caribbean n = 2
Other group n = 2
Excluded n = 50
Other groups
Figure 1. Participant selection process.
Of the 555 participants entering analysis, 
286 (52%) self-identified as black males 
and 269 (48%) as white males. Black males 
were younger (74% aged 40–59 years) and 
a greater percentage were in full-time 
employment compared with their white 
counterparts (42% versus 19%). Just over 
half of the group of white males had retired. 
More white males (59%) than black males 
(39%) had a family member or friend with a 
history of cancer. 
Preference for investigation 
Overall, 81% of the participants opted for 
investigation. Participants’ preferences 
for investigation differed by ethnicity with 
94% of white males opting for investigation 
regardless of risk levels and 70% of black 
males doing so. The difference between 
the groups was most marked at the lowest 
risk level: just 44% of black males opted for 
investigation compared with 91% of white 
males (Table 3). 
After controlling for participants’ age, 
employment status, convenience of hospital, 
and previous history of cancer (none of 
which was independently associated with 
opting for investigation), plus prostate 
cancer risk level, the odds of opting for 
investigation remained significantly lower 
in black males (odds ratio [OR] 0.13; 95% 
confidence interval [CI] = 0.07 to 0.25; 
P<0.001) (Table 3). A test of interaction 
showed little evidence that the OR differed 
by level of risk (P = 0.41).
Reason for choice
Although the main reason cited by males 
of both groups was early diagnosis, a much 
higher proportion of white males selected 
this option. In black males, peace of mind 
was almost as important (Table 4).
 Fewer white males than black males 
gave their reasons for declining investigation 
although, again, differences were significant 
(Table 4). 
For males in both groups, the main 
reason cited for declining investigation was 
low risk of cancer; however, a considerably 
higher proportion of black males stated that 





In this study, it was found that black males 
opt for investigation for possible prostate 
cancer less frequently than white males; 
this did not appear to be related to any 
specific, recorded, patient characteristic. 
This lower preference for investigation 
in black males was particularly marked 
when the risk of cancer in the vignette was 
low: less than half of black males opted 
for investigation when the risk of prostate 
cancer was the lowest value offered 
(namely 2%). In contrast, white males had 
a very high preference for investigation, 
including at the 2% risk level. 
Several factors were not significantly 
associated with black males' preferences 
for investigation, including age, income, 
employment status, convenience of the 
nearest main hospital, or a family history 
of cancer.
Strengths and limitations 
To the authors' knowledge, this is the first 
study to examine ethnic differences in the 
desire to be tested for prostate cancer. 
This study built on a previous, successful 
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Table 3. Preference for testing in black males and white males
 Black  White       
Level of risk, % males,% (n) males,% (n) COR AORa 95% CI P-value
2 44 (40/90) 91 (98/108)
5 82 (79/96) 97 (83/86)
10 80 (79/99) 96 (70/73)
All  70 (198/285) 94 (251/267) 0.15 0.13  0.07 to 0.25 <0.001 
AOR = adjusted odds ratio. COR = crude odds ratio. aAdjusted for participants’ age, employment status, 
convenience of hospital, previous history of cancer (none of which was independently associated with opting for 
investigation), and prostate cancer risk level.
Table 4. Main reasons cited for investigation preferences in black 
males and white males
 Black males, % White males, %  
Main reason for choosing investigation n = 197 n = 251 P-valuea 
Having the cancer test would give me peace of mind 41 15 
Having the cancer test would allow cancer to be found early 45 72 
If the test is offered I’ll take it 11 9 
0.001
Having the test would be easy 1 0 
My family/friends would want me to have the cancer test 1 0
At my age, I think a cancer test is worthwhile 1 3 
 Black males, %  White males, % 
Main reason for declining investigation n = 85 n = 14
The risk of cancer is not very high 45 43
I would rather not know I have cancer 37 14
The cancer test sounds unpleasant 12 7
The cancer test can cause damage  1 7 <0.001
The cancer test would be too inconvenient  0 0
Getting to hospital for the cancer test would be difficult 0 0
At my age, a cancer test is not worthwhile 2 29
If I have cancer, early diagnosis would not help 4 0
a c2 test P-value. 
project that was not powered to explore 
ethnic differences; as a result, much of 
the design and piloting for this study had 
already been performed, and procedural 
problems overcome. 
The vignettes were realistic and used 
primary care data to provide estimates of the 
actual risk of prostate cancer.11 In addition, 
the electronic nature of the questionnaire 
minimised missing data and was accepted 
by 80% of patients who often have a long 
waiting time, with few or no distractions. The 
response rate of >80% was excellent, and 
there was no obvious difference by ethnic 
groups in those declining to participate.
However, some limitations are present. 
Black male patients (who have a higher 
incidence rate for prostate cancer) were 
compared with white male patients; as a 
result, the findings cannot be generalised 
beyond these two groupings. In addition, 
two black ethnicities (black–black British 
African and black–black British Caribbean) 
were grouped together; there are many 
different black ethnic groups, which may 
have different views on the advantages of 
testing for prostate cancer. 
A further limitation is that only prostate 
cancer was studied so it is not possible to 
determine whether the lower preference for 
investigation in black males would also be 
found for other cancers, or in black females. 
Furthermore, the sample population 
comprised GP attenders. Although 
conducting the study in the GP practice 
offered the major advantage of providing 
translation where needed, and being the 
setting where initial investigation for prostate 
cancer takes place, it is not possible 
to determine whether a true community 
sample, or a sample in other cities, would 
have yielded different results. That said, there 
is no reason to think this would be the case. 
The final consideration is whether 
vignettes give valid answers. This was 
discussed relatively widely in Banks et al ’s 
recent study: most, but not all, studies 
considered vignettes to provide meaningful 
responses.12 
Comparison with existing literature
Overall, 81% of the sample participants 
opted for investigation in the first vignette. 
This proportion is lower than the 88% 
reported in Banks et al ’s study (although 
89% of participants in that study were white 
British); the differences by risk groups in 
that study were also slightly larger. In the 
study reported here, 94% of white males 
opted for investigation; this may reflect the 
different cancer site: prostate, as opposed 
to colon, pancreas, or lung. Prostate cancer 
is generally found in older males, has lower 
mortality rates, and is relatively more 
common in black males; all of these factors 
make it somewhat atypical.
There was a general increase in the 
preference for investigation with higher risk 
of cancer in black males; a finding reported 
by Banks et al,12 although in that case it was 
largely driven by their colorectal findings. 
The rationale appears logical; it was not 
seen in white males but this could be a 
result of their high overall preference for 
investigation.
This study's findings of a lower preference 
for investigation in black males, compared 
with white males, could perhaps indicate 
why it has been found that emergency 
presentations are increased, and mortality 
and staging at diagnosis are worse, in 
black males.3,4,15 The current findings are 
based on a vignette that presupposed 
entry into health care, and strictly does 
not extrapolate on the decision to seek 
health care when a man has symptoms; 
however, it is plausible that a lower desire 
for investigation may also engender a lower 
desire to seek help. 
Black males have been reported to 
have a worse fear of prostate cancer when 
compared with white males.4,16 They fear 
that the disease could be terminal and that 
its treatment could lead to severe sexual 
disorders (such as erectile dysfunction, 
sterility, and decreased sex drive), which, in 
turn, may change their close relationships 
with their spouses.16,17 Several (mainly US) 
studies have highlighted fear as a major 
deterrent to black males' medical help-
seeking, even when experiencing lower 
urinary tract symptoms.16 This factor may 
explain some of the views expressed by 
black males in this study rather than 
assuming that they were making accurate 
judgement of their cancer risk. It is also 
well recognised that black males do not 
like visiting doctors and may be influenced 
in their healthcare seeking by family 
members;18,19 interestingly, however, a 
specific family history of cancer did not 
appear to be important in the current study.
Conversely, patients’ knowledge of 
prostate cancer signs and symptoms, 
investigative procedures, and possible 
outcomes of treatments may influence 
their willingness for investigation.17,20 Males 
of both ethnicities have similar knowledge 
of prostate risks and symptoms,4 although 
black males tend to underestimate their 
personal risk of the disease,21 and are often 
less conversant with the PSA and rectal 
examination procedures, and may abstain 
from investigation altogether due to 
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this.17,20 Some black males perceive rectal 
examination as a threat to their masculinity 
and consider it an undignified test.17,20 They 
are also more likely to be too embarrassed 
about lower urinary tract symptoms and 
generally less comfortable seeing their GPs 
compared with their white counterparts.4,22 
These factors, in addition to language or 
communication barriers, stigma, and 
socioeconomic deprivation may provide 
an alternative explanation to black males' 
reluctance for prostate cancer investigation 
when symptomatic. 
Models of behavioural change (for 
example, the health belief model and self-
regulatory models) have been used to 
explain patients’ attitudes towards cancer 
screening and early diagnosis.23,24 The 
questionnaire in this study did not collect 
specific information to assess this, although 
the main reasons cited by participants for 
choosing or declining investigation provide 
useful insights in this regard. In total, 86% of 
those declining prostate cancer investigation 
were black males, around half of whom cited 
low risks as the main reason for their choice. 
This is consistent with the findings of a US 
study, which reported moderate perceived 
susceptibility and perceived severity of 
prostate cancer in black males.24 Worryingly, 
37% of those who declined indicated that 
they would rather not know they have cancer; 
this, again, echoes their fears of the disease 
and perceived negative consequences of it 
being diagnosed. 
In both groups who opted for investigation, 
early detection of prostate cancer was the 
main reason cited for their decision, and 
black males cited peace of mind almost 
as frequently. White male reasoning in this 
situation may be interpreted in line with 
their perceived benefits of treatment and 
curability of the disease, while black males' 
views may, again, reflect their greater fear 
of prostate cancer diagnosis and possible 
treatment outcomes. 
Implications for practice
The pathway to diagnosis of symptomatic 
prostate cancer is complex, the success 
of which depends largely on prompt 
presentation of symptoms to primary care 
and prompt referral to secondary or specialist 
care. Both stages may be influenced 
by patients’ preference for diagnostic 
investigation. GPs should be aware of the 
reduced appetite for testing in black males 
(which is possibly linked to fear and perceived 
negative outcomes of a prostate cancer 
diagnosis) and may consider being proactive 
in discussing the subject. This is particularly 
important as a study has suggested lower 
self-initiated discussion with the doctor about 
prostate cancer in black Caribbean males (as 
measured in native-born and foreign-born 
black males in the US).25
Prostate cancer awareness campaigns 
currently targeting black males may prove 
less effective where patients are unwilling to 
take up diagnostic investigation. Campaigners 
may consider including information about 
testing procedures and promote the benefits 
of early diagnosis. This is especially relevant 
as black community groups are increasingly 
keen to see PSA screening become available. 
If such campaigns could also incorporate 
encouragement for symptomatic testing, 
the differences reported in this study may 
narrow.
Black males, who have a higher incidence 
of prostate cancer and a higher mortality 
from it, are less inclined than white males 
to be tested for the disease. Education 
targeted at the black community and the 
health professionals who treat them may 
help to address this. 
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Appendix 1. The vignette as viewed by participants. 
e169  British Journal of General Practice, March 2015
Appendix 1 continued. The vignette as viewed by participants. 
British Journal of General Practice, March 2015  e170
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